BioMarin (BMRN) Higher as Takeover Chatter Swirls
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Join SI Premium – FREE
Shares of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) are seeing pre-open action Tuesday following reports overseas that GlaxoSmithKline plc (NYSE: GSK) could be eying a takeover of the company.
The news comes as GlaxoSmithKline is currently pursuing a hostile deal to acquire Human Genome Sciences (Nasdaq: HGSI), which has rejected GSK's $13 per share bid.
GSK is not the only one interested in BioMarin however. Last week it was reported that Shire plc (Nasdaq: SHPGY) was also stalking the company.
The reports, while very speculative in nature, have traders snapping up shares of BioMarin. They may believe where there's smoke there's fire. Shares are up nearly 7 percent in pre-open trading to $38.
The news comes as GlaxoSmithKline is currently pursuing a hostile deal to acquire Human Genome Sciences (Nasdaq: HGSI), which has rejected GSK's $13 per share bid.
GSK is not the only one interested in BioMarin however. Last week it was reported that Shire plc (Nasdaq: SHPGY) was also stalking the company.
The reports, while very speculative in nature, have traders snapping up shares of BioMarin. They may believe where there's smoke there's fire. Shares are up nearly 7 percent in pre-open trading to $38.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alibabato sell Lingxi Games in more than $2B deal - Reuters
- Arxis completes $770M acquisition of Omnetics Connector
- Curaleaf launches hostile takeover bid for Aurora Cannabis at $4/share
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
